Phase II Randomized Double-Blinded Placebo-Controlled study that will evaluate the efficacy safety and tolerability of natalizumab as adjunctive therapy in adult subjects with drug-resistant focal epilepsy.
Brief description of study
The main purpose of this study is to see how well natalizumab works in subjects with focal epilepsy (when seizures start in a region of the brain). Subjects who participate in this study have seizures that did not fully improve and still occur frequently after taking 2 or more anti-epileptic drugs (AEDs) and that still occur frequently. This study will see if the number of seizures subjects experience decreases while taking the study drug and how safe the study drug is. The study drug will be given as an additional therapy alongside the subjects' usual AEDs.
Clinical Study Identifier: s17-01037
ClinicalTrials.gov Identifier: NCTs17-01037
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
